Literature DB >> 1516596

Patients with anticardiolipin antibodies with and without antiphospholipid syndrome: their clinical features and beta 2-glycoprotein-I plasma levels.

P G Vlachoyiannopoulos1, S A Krilis, J E Hunt, M N Manoussakis, H M Moutsopoulos.   

Abstract

The clinical and serological features of 38 aCL-positive patients were compared to those of 45 aCL-negative patients. A significantly higher incidence of thrombophlebitis and livedo reticularis was found in aCL-positive patients. There were 13 aCL positive patients with thrombophlebitis and/or arterial thromboses and these 13 patients were designated as having the antiphospholipid syndrome (APS) while the remaining 70 patients were diagnosed as having Systemic Lupus Erythematosus (SLE). APS patients also had a high incidence of arterial occlusions, recurrent abortions and strokes compared to SLE patients. Patients with high levels of IgG-aCL were more likely to have APS, while patients with low levels of IgG-aCL or IgM-aCL only were more likely to have SLE without the clinical features of APS. Since aCL antibodies have recently been shown to interact with a phospholipid-binding plasma protein beta 2-glycoprotein-I (beta 2-GPI), we measured the beta 2-GPI levels in these patients and found that beta 2-GPI levels are significantly higher in APS compared to SLE patients negative for aCL antibodies. Since beta 2-GPI is known to exert multiple effects on coagulation processes the interaction of aCL antibodies with this glycoprotein may play a pathogenic role in APS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516596     DOI: 10.1111/j.1365-2362.1992.tb01494.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Value of anticardiolipin antibodies for monitoring disease activity in systemic lupus erythematosus and other rheumatic diseases.

Authors:  F Buttgereit; T Grünewald; W Schüler-Maué; G R Burmester; F Hiepe
Journal:  Clin Rheumatol       Date:  1997-11       Impact factor: 2.980

2.  Antibodies to beta 2-glycoprotein-I: urea resistance, binding specificity, and association with thrombosis.

Authors:  P G Vlachoyiannopoulos; C Petrovas; M Tektonidou; S Krilis; H M Moutsopoulos
Journal:  J Clin Immunol       Date:  1998-11       Impact factor: 8.317

3.  Detection of anti-bovine beta 2-glycoprotein I antibody in sera from patients with antiphospholipid syndrome.

Authors:  M Nomura; J Okada; H Kondo
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

4.  Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I.

Authors:  Yiannis Ioannou; Jing-Yun Zhang; Miao Qi; Lu Gao; Jian Cheng Qi; De-Min Yu; Herman Lau; Allan D Sturgess; Panayiotis G Vlachoyiannopoulos; Haralampos M Moutsopoulos; Anisur Rahman; Charis Pericleous; Tatsuya Atsumi; Takao Koike; Stephane Heritier; Bill Giannakopoulos; Steven A Krilis
Journal:  Arthritis Rheum       Date:  2011-09

5.  Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome.

Authors:  Fatima El-Assaad; Steven A Krilis; Bill Giannakopoulos
Journal:  Thromb J       Date:  2016-10-04

6.  Redox Status of β2GPI in Different Stages of Diabetic Angiopathy.

Authors:  Jun Ma; Jing-Yun Zhang; Yan Liu; De-Min Yu; Pei Yu
Journal:  Dis Markers       Date:  2016-10-13       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.